

Tuvonralimab

Cat. No.:	HY-P99540
CAS No.:	2417649-44-4
Target:	PD-1/PD-L1; CTLA-4
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab ^[1] .
In Vitro	Tuvonralimab contains mutations for heavy and light chain pairing (HC mutations K147D/F170C/V173C/C220G/R255K/D399R/K409E; light chain mutations S131K/Q160C/S162C/C214S), but not for the generation of a bispecific antibody. The final drug substance is a mixture of two monospecific IgGs, Iparomlimab and Tuvonralimab. The two antibodies are produced from the same cell line, with the mutations within Tuvonralimab ensuring efficient pairing of the correct chains. Iparomlimab contains no mutations ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ian Wilkinson, et al. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. *MAbs*. 2022 Jan-Dec;14(1):2123299.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA